首页> 外文期刊>Human cell: official journal of Human Cell Research Society >Reversible transformation and de-differentiation of human cells derived from induced pluripotent stem cell teratomas.
【24h】

Reversible transformation and de-differentiation of human cells derived from induced pluripotent stem cell teratomas.

机译:源自诱导性多能干细胞畸胎瘤的人类细胞的可逆转化和去分化。

获取原文
获取原文并翻译 | 示例
           

摘要

We first aimed to generate transformed cell lines from a human induced pluripotent stem cell (hiPSC)-teratoma, and then examined the tumorigenic risks of the differentiated cells from hiPSC explant, because hiPSC-derivatives give rise to tumors in immune-deficient mice when transplanted. The colonies isolated from sparse cultures of hiPSC-teratoma cells expressed NANOG and OCT3/4 strongly, and telomerase reverse transcriptase (TERT) weakly. However, soft agar assay demonstrated that only one of them generated colonies in the gel, though hiPSCs, hTERT-transfected immortal cells, and its oncogene-transfected cells did not form any colonies. Furthermore, none of colonies isolated from the soft agar gel on primary culture (passage 0) of teratoma cells, expressed NANOG and OCT3/4 in the expanded cultures. The second soft agar assay on the colony-derived cells was unexpectedly negative. The cumulative growth curve, telomere shortening, and senescence-associated β-galactosidase (SA β-gal) staining confirmed the mortality of these cells, suggesting their reversible transformation. By using medium for embryonic stem cell (ESC medium) after MCDB 131 (MCDB) medium, the differentiated culture cells derived from hiPSC-teratoma converted into the cells expressing undifferentiated marker proteins, which lost afterwords even in ESC medium with feeder SNL76/7. The reversibility of transformation and de-differentiation suggest that tumorigenic risks of differentiated cells arise when they are exposed to suitable niches in vivo. Thus, removal of only the undifferentiated cells from iPSC-derivatives before transplantation does not solve the problem. Elucidation of mechanisms of reversibility and control of epigenetic changes is discussed as a safety bottleneck for hiPSC therapy.
机译:我们首先旨在从人诱导的多能干细胞(hiPSC)-畸胎瘤产生转化的细胞系,然后研究了从hiPSC外植体分化的细胞的致瘤风险,因为在移植时,hiPSC衍生物会在免疫缺陷小鼠中引起肿瘤。 。从稀疏的hiPSC-畸胎瘤细胞培养物中分离出的菌落强烈表达NANOG和OCT3 / 4,而端粒酶逆转录酶(TERT)则较弱。然而,软琼脂分析表明,尽管hiPSC,hTERT转染的永生细胞及其癌基因转染的细胞未形成任何菌落,但只有一种在凝胶中产生菌落。此外,在畸胎瘤细胞的原代培养(第0代)中没有从软琼脂凝胶分离的菌落在扩展培养物中表达NANOG和OCT3 / 4。菌落衍生细胞的第二次软琼脂测定出乎意料地阴性。累积生长曲线,端粒缩短和衰老相关的β-半乳糖苷酶(SAβ-gal)染色证实了这些细胞的死亡率,表明它们可逆转化。通过在MCDB 131(MCDB)培养基之后使用胚胎干细胞培养基(ESC培养基),从hiPSC-畸胎瘤获得的分化培养细胞转化为表达未分化标记蛋白的细胞,甚至在带有饲养者SNL76 / 7的ESC培养基中也失去了后遗症。转化和去分化的可逆性表明,分化的细胞在体内暴露于合适的壁ni时会产生致癌风险。因此,在移植前仅从iPSC衍生物中去除未分化的细胞并不能解决问题。阐明可逆性机制和表观遗传变化的控制是hiPSC治疗的安全瓶颈。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号